Study #2020-0745
A randomized, open-label, multi-arm, two-part, phase II study to assess the efficacy and safety of multiple LXH254 combinations in patients with previously treated unresectable or metastatic BRAFV600 or NRAS mutant melanoma
MD Anderson Study Status
Not Accepting
Treatment Agent
LXH254, LTT462, Trametinib, Ribociclib
Description
The primary purpose of this study is to evaluate the efficacy of LXH254 combinations in previously treated unresectable or metastatic melanoma
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Melanoma
Study phase:
Phase II
Physician name:
Rodabe Amaria
Department:
Melanoma Medical Oncology
For general questions about clinical trials:
1-866-478-2259
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.